



## AtriCure Reports Second Quarter 2021 Financial Results

August 4, 2021

MASON, Ohio--(BUSINESS WIRE)--Aug. 4, 2021-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results.

“Our second quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward making our platforms the standard of care,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are poised for accelerating growth with the recent FDA approval of our EPI-Sense® System to improve the lives of millions of patients with long-standing persistent Afib. This approval enriches the foundation of our Company, built on core technologies which continue to deliver solid growth as we address vastly underpenetrated markets.”

### **Second Quarter 2021 Financial Results**

Revenue for the second quarter of 2021 was \$71.4 million, an increase of 74.8% (an increase of 73.5% on a constant currency basis) over second quarter 2020 revenue. U.S. revenue was \$60.1 million, an increase of \$26.4 million or 78.4%, compared to second quarter 2020 revenue. U.S. revenue growth was seen across all product lines, driven by the receding impact of the COVID-19 pandemic in 2021 which resulted in stabilizing cardiac surgery procedure volumes and increasing demand. International revenue increased \$4.1 million or 57.9% (an increase of 50.2% on a constant currency basis) to \$11.3 million, reflecting growth in most major markets and across product lines. On a sequential basis, worldwide revenue for the second quarter 2021 increased approximately 20% over first quarter 2021.

Gross profit for the second quarter of 2021 was \$54.1 million compared to \$27.7 million for the second quarter of 2020. Gross margin was 75.8% and 67.7% for the second quarters of 2021 and 2020 respectively, reflecting the increase in revenue and reduced fixed cost burden on cost of revenue with the return to normal production in 2021, along with the favorable impact of both geographic and product mix.

Loss from operations for the second quarter of 2021 was \$15.1 million, compared to \$7.3 million for the second quarter of 2020. Net loss per share was \$0.36 for the second quarter of 2021, compared to \$0.20 for the second quarter of 2020.

Adjusted EBITDA was a loss of \$2.7 million for the second quarter of 2021 compared to a \$6.1 million loss for the second quarter of 2020. Adjusted loss per share for the second quarter of 2021 was \$0.30 compared to \$0.38 for the second quarter of 2020.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release.

### **2021 Financial Guidance**

Management is updating revenue guidance for full year 2021 to a range of \$270 to \$275 million, corresponding to growth of approximately 31% to 33% for the year. As with previous guidance, continued uncertainty relating to the dynamic environment with the COVID-19 pandemic could materially impact this projection. The Company is maintaining guidance for full year 2021 adjusted EBITDA loss of approximately \$10 million, and updating guidance for an adjusted loss per share of approximately \$1.20.

### **Conference Call**

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 4, 2021 to discuss its second quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 8299332. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at [ir.atricure.com](http://ir.atricure.com). A replay of the presentation will be available for 90 days following the presentation.

### **About AtriCure**

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit [AtriCure.com](http://AtriCure.com) or follow us on Twitter [@AtriCure](https://twitter.com/AtriCure).

### **Forward-Looking Statements**

This press release contains “forward-looking statements”— that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit <http://www.atricure.com/fls> as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements.

### **Use of Non-GAAP Financial Measures**

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates, which are determined by the average daily Euro to Dollar exchange rate, to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a

non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as Net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement costs, and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned "Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)" later in this release.

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities and legal settlement costs. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned "Reconciliation of Non-GAAP Adjusted Loss Per Share" later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure's financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

**ATRICURE, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(In Thousands, Except Per Share Amounts)  
(Unaudited)

|   | Three Months Ended June<br>30, |            | Six Months Ended June 30, |             |
|---|--------------------------------|------------|---------------------------|-------------|
|   | 2021                           | 2020       | 2021                      | 2020        |
| United States Revenue:  |                                |            |                           |             |
| Open ablation   | \$ 24,839                      | \$ 15,550  | \$ 45,914                 | \$ 34,768   |
| Minimally invasive ablation                                   | 9,702                          | 4,755      | 18,087                    | 11,316      |
| Appendage management  | 25,156                         | 13,021     | 45,743                    | 30,440      |
| Total ablation and appendage management                       | 59,697                         | 33,326     | 109,744                   | 76,524      |
| Valve tools   | 373                            | 338        | 635                       | 613         |
| Total United States   | 60,070                         | 33,664     | 110,379                   | 77,137      |
| International Revenue:  |                                |            |                           |             |
| Open ablation   | 5,513                          | 3,744      | 9,930                     | 8,859       |
| Minimally invasive ablation                                   | 1,575                          | 1,109      | 2,849                     | 2,654       |
| Appendage management  | 4,194                          | 2,271      | 7,452                     | 5,333       |
| Total ablation and appendage management                       | 11,282                         | 7,124      | 20,231                    | 16,846      |
| Valve tools   | 24                             | 36         | 41                        | 66          |
| Total international   | 11,306                         | 7,160      | 20,272                    | 16,912      |
| Total revenue   | 71,376                         | 40,824     | 130,651                   | 94,049      |
| Cost of revenue   | 17,298                         | 13,170     | 32,033                    | 27,511      |
| Gross profit  | 54,078                         | 27,654     | 98,618                    | 66,538      |
| Operating expenses:   |                                |            |                           |             |
| Research and development expenses                             | 12,197                         | 10,036     | 23,414                    | 21,623      |
| Selling, general and administrative expenses                  | 56,958                         | 24,903     | 106,166                   | 67,654      |
| Total operating expenses                                      | 69,155                         | 34,939     | 129,580                   | 89,277      |
| Loss from operations  | (15,077)                       | (7,285)    | (30,962)                  | (22,739)    |
| Other expense, net  | (1,108)                        | (939)      | (2,109)                   | (1,885)     |
| Loss before income tax expense                                | (16,185)                       | (8,224)    | (33,071)                  | (24,624)    |
| Income tax expense (benefit)                                  | 66                             | 12         | 97                        | 20          |
| Net loss  | \$ (16,251)                    | \$ (8,236) | \$ (33,168)               | \$ (24,644) |
| Basic and diluted net loss per share                          | \$ (0.36)                      | \$ (0.20)  | \$ (0.74)                 | \$ (0.61)   |
| Weighted average shares used in computing net loss per share: |                                |            |                           |             |
| Basic and diluted   | 45,035                         | 41,649     | 44,834                    | 40,160      |

**ATRICURE, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In Thousands)  
(Unaudited)

|   | <b>June 30,<br/>2021</b> | <b>December 31,<br/>2020</b> |
|---|--------------------------|------------------------------|
| <b>Assets</b>   |                          |                              |
| Current assets:   |                          |                              |
| Cash, cash equivalents, and short-term investments                  | \$ 159,865               | \$ 244,218                   |
| Accounts receivable, net  | 33,835                   | 23,146                       |
| Inventories   | 37,608                   | 35,026                       |
| Prepaid and other current assets                                    | 4,636                    | 4,347                        |
| Total current assets  | 235,944                  | 306,737                      |
| Property and equipment, net   | 30,175                   | 28,290                       |
| Operating lease right-of-use assets                                 | 2,683                    | 1,914                        |
| Long-term investments   | 69,770                   | 14,178                       |
| Goodwill and intangible assets, net                                 | 362,015                  | 362,980                      |
| Other noncurrent assets   | 488                      | 440                          |
| Total assets  | \$ 701,075               | \$ 714,539                   |
| <b>Liabilities and Stockholders' Equity</b>                         |                          |                              |
| Current liabilities:  |                          |                              |
| Accounts payable and accrued liabilities                            | \$ 48,940                | \$ 40,720                    |
| Other current liabilities and current maturities of debt and leases | 18,493                   | 8,417                        |
| Total current liabilities   | 67,433                   | 49,137                       |
| Long-term debt  | 43,669                   | 53,435                       |
| Finance lease liabilities   | 10,540                   | 10,969                       |
| Operating lease liabilities   | 1,833                    | 1,180                        |
| Contingent consideration and other noncurrent liabilities           | 192,517                  | 187,424                      |
| Total liabilities   | 315,992                  | 302,145                      |
| Stockholders' equity:   |                          |                              |
| Common stock  | 46                       | 45                           |
| Additional paid-in capital  | 748,644                  | 742,389                      |
| Accumulated other comprehensive (loss) income                       | (87)                     | 312                          |
| Accumulated deficit   | (363,520)                | (330,352)                    |
| Total stockholders' equity  | 385,083                  | 412,394                      |
| Total liabilities and stockholders' equity                          | \$ 701,075               | \$ 714,539                   |

**ATRICURE, INC. AND SUBSIDIARIES**  
**RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS**  
(In Thousands)  
(Unaudited)

**Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)**

|                                       | <b>Three Months Ended June<br/>30,</b> |             | <b>Six Months Ended June 30,</b> |             |
|---------------------------------------|--|-------------|----------------------------------|-------------|
|                                       | <b>2021</b>                            | <b>2020</b> | <b>2021</b>                      | <b>2020</b> |
| Net loss, as reported                 | \$ (16,251)                            | \$ (8,236)  | \$ (33,168)                      | \$ (24,644) |
| Income tax expense                    | 66                                     | 12          | 97                               | 20          |
| Other expense, net                    | 1,108                                  | 939         | 2,109                            | 1,885       |
| Depreciation and amortization expense | 2,658                                  | 2,458       | 4,780                            | 4,902       |
| Share-based compensation expense      | 7,141                                  | 6,193       | 13,745                           | 10,577      |
| Contingent consideration adjustment   | 2,600                                  | (7,504)     | 5,100                            | (5,046)     |
| Acquisition costs                     | —                                      | 39          | —                                | 138         |
|                                       | —                                      | 39          | —                                | 138         |

|  |            |            |            |             |
|--|------------|------------|------------|-------------|
| Non-GAAP adjusted loss (adjusted EBITDA) | \$ (2,678) | \$ (6,099) | \$ (7,337) | \$ (12,168) |
|--|------------|------------|------------|-------------|

#### Reconciliation of Non-GAAP Adjusted Loss Per Share

|   | Three Months Ended June 30, |             | Six Months Ended June 30, |             |
|---|-----------------------------|-------------|---------------------------|-------------|
|   | 2021                        | 2020        | 2021                      | 2020        |
| Net loss, as reported   | \$ (16,251)                 | \$ (8,236)  | \$ (33,168)               | \$ (24,644) |
| Contingent consideration adjustment                                   | 2,600                       | (7,504)     | 5,100                     | (5,046)     |
| Net loss excluding contingent consideration adjustment                | \$ (13,651)                 | \$ (15,740) | \$ (28,068)               | \$ (29,690) |
| Basic and diluted adjusted net loss per share                         | \$ (0.30)                   | \$ (0.38)   | \$ (0.63)                 | \$ (0.74)   |
| Weighted average shares used in computing adjusted net loss per share |                             |             |                           |             |
| Basic and diluted   | 45,035                      | 41,649      | 44,834                    | 40,160      |

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210804005943/en/): <https://www.businesswire.com/news/home/20210804005943/en/>

Angie Wirick  
AtriCure, Inc.  
Chief Financial Officer  
(513) 755-5334  
[awirick@atricure.com](mailto:awirick@atricure.com)

Lynn Pieper Lewis  
Gilmartin Group  
Investor Relations  
(415) 937-5402  
[lynn@gilmartinir.com](mailto:lynn@gilmartinir.com)

Source: AtriCure, Inc.